Richard Stewart
2022
In 2022, Richard Stewart earned a total compensation of $1.3M as Executive Chairman at OncoGenex Pharmaceuticals, a 5% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $175,000 |
|---|---|
| Option Awards | $322,803 |
| Salary | $400,000 |
| Stock Awards | $371,700 |
| Total | $1,269,503 |
Stewart received $400K in salary, accounting for 32% of the total pay in 2022.
Stewart also received $175K in non-equity incentive plan, $322.8K in option awards and $371.7K in stock awards.
Rankings
In 2022, Richard Stewart's compensation ranked 2,567th out of 5,711 executives tracked by ExecPay. In other words, Stewart earned more than 55.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,567 out of 5,711 | 55th |
Division Manufacturing | 1,419 out of 3,109 | 54th |
Major group Chemicals And Allied Products | 643 out of 1,410 | 54th |
Industry group Drugs | 597 out of 1,311 | 55th |
Industry In Vitro and In Vivo Diagnostic Substances | 9 out of 29 | 69th |
Source: SEC filing on April 28, 2023.
Stewart's colleagues
We found two more compensation records of executives who worked with Richard Stewart at OncoGenex Pharmaceuticals in 2022.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019